bioAffinity Technologies focuses on the early detection and treatment of lung cancer through innovative diagnostic solutions. Their flagship product, CyPath® Lung, utilizes advanced flow cytometry to analyze sputum samples, providing a non-invasive method for diagnosing early-stage lung cancer. This test is particularly beneficial for patients with suspicious findings from low-dose computed tomography (LDCT), which often has a high false positive rate. By characterizing cell populations in the lung micro-environment, CyPath® Lung aims to improve diagnostic accuracy, reduce unnecessary invasive procedures, and ultimately enhance patient outcomes.

The technology behind CyPath® Lung involves the automated analysis of sputum, where specific porphyrin labels are used to identify cancerous cells. This method allows for rapid processing and results delivery, with physicians receiving test outcomes within three days of sample arrival at the lab. The platform has demonstrated high sensitivity and specificity in clinical studies, making it a promising tool for lung cancer screening. Additionally, bioAffinity Technologies is actively engaged in research and development to expand its diagnostic capabilities and therapeutic applications, further solidifying its commitment to combating cancer at the cellular level.

United States

Addressing a critical need to find cancer early and treat cancer specifically, bioAffinity Technologies, Inc. develops tests and therapies to detect and treat cancer at the cellular level. 

Our first product, CyPath® Flow Cytometry for Lung Cancer (CyPath® Lung), has been licensed by Precision Pathology Services for continued development and commercial sale as a Laboratory Developed Test. 

CyPath® Lung has the potential to dramatically increase overall diagnostic accuracy leading to increased survival, fewer unnecessary invasive procedures and lower patient anxiety and medical costs.

bioAffinity Technologies

Company Details